MAPLE GROVE, Minn., Oct. 27, 2026 /PRNewswire/ -- Vincora (NeoChord, Inc. d/b/a Vincora), a medical technology company developing transcatheter therapies for mitral valve repair, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) to initiate a U.S. Early Feasibility Study (EFS) of its investigational Transcatheter Chordal Repair System for the treatment of degenerative mitral valve regurgitation.